Abstract

Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a long follow-up by immunohistochemistry. They show that SPARC expression was detected in cancer cells (42.4%), cancer-associated fibroblasts (CATs) (88.1%). TAMs (77.1%), endothelial cells (75.2%) and TILs (9.8%). Recurrence-free survival (RFS) was significantly lower for patients with a positive expression of SPARC in CATs (SPARC+CATs) with a median follow-up of 5.4 years. SPARC expression in CATs was found to be an independent prognostic factor in multivariate analysis. Accordingly, the present invention relates to a method for predicting the survival time of a subject suffering from triple-negative breast cancer (TNBC) comprising determining the expression level of Secreted Protein Acidic and Rich in Cysteine (SPARC) in cancer-associated fibroblasts (CATs) in a biological sample obtained from the subject wherein said positive expression of SPARC in CATs (SPARC+CAFs) correlates with a short survival time of the subject.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1 x106to 3x106 international units (IU) and the subject has a low to medium concentration of p-NFH in cerebrospinal fluid (CSF p-NFH) or a low to medium concentration of NFL or NFM in cerebrospinal fluid, blood, serum or plasma before human IL-2 administration. The invention also relates to medical uses where the CSF p-NFH or CSF, blood, serum or plasma NFL or NFM concentration is used to select the best administration scheme or as a biomarker for stratified randomization of a cohort of ALS patients in the context of a clinical trial assessing the therapeutic efficiency of a candidate ALS treatment.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a long follow-up by immunohistochemistry. They show that SPARC expression was detected in cancer cells (42.4%), cancer-associated fibroblasts (CATs) (88.1%), TAMs (77.1%), endothelial cells (75.2%) and TILs (9.8%). Recurrence-free survival (RFS) was significantly lower for patients with a positive expression of SPARC in CATs (SPARC+ CATs) with a median follow-up of 5.4 years. SPARC expression in CATs was found to be an independent prognostic factor in multivariate analysis. Accordingly, the present invention relates to a method for predicting the survival time of a subject suffering from triple-negative breast cancer (TNBC) comprising determining the expression level of Secreted Protein Acidic and Rich in Cysteine (SPARC) in cancer-associated fibroblasts (CATs) in a biological sample obtained from the subject wherein said positive expression of SPARC in CATs (SPARC+CAFs) correlates with a short survival time of the subject.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU) Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 HI human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention concerns a composition comprising an Angiotensin receptor 1 (AT1) inhibitor and one or more other active compounds selected from the group consisting of antioxidants, caspase inhibitors, and mixtures thereof, for use as a drug in subjects in need thereof, for preventing and/or treating viral infections due to at least one betacoronavirus, in particular for preventing severe forms of viral infections due to betacoronavirus, in particular COVID-19 due to SARS-CoV-2.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof

Abstract

A method for diagnosing or prognosing, multiple sclerosis including the steps of (a) measuring the amount of at least one first protein as set forth in SEQ ID NO: 1, the at least first protein belonging to the group of proteins: a first protein, a second protein, a third protein, a fourth protein and a fifth protein, as set forth in SEQ ID NO 1 to 5, (b) comparing the amount of the at least first protein with the amount of the same protein in a control sample, and (c) determining the status of the biological sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1 x106 to 3x106 international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1 x106 to 3x106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1 x106to 3x106international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1 x106to 3x106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a method for diagnosing or prognosing, multiple sclerosis comprising the steps of: a. Measuring, the amount of at least one first protein as set forth in SEQ ID NO: 1, said at least first protein belonging to the group of proteins consisting of a first protein, a second protein, a third protein, a fourth protein and a fifth protein, as set forth in SEQ ID NO 1 to 5, b. comparing the amount of said at least first protein with the amount of the same protein in a control sample, and c. determining the status of said biological sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61B 17/435 - Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo transplantation

Abstract

The invention relates to a system for non-invasive biomorphological characterisation of a human limb (110), comprising a geometric and volumetric measurement device (100) comprising: - a plurality of three-dimensional image acquisition systems (131-137) designed to image said limb (110), - an articulated and motorised frame (120), designed to position and move at least one part of the plurality of acquisition systems (131-137) in a peripheral manner to said limb (110), - a processing device for processing geometric and volumetric data, designed to represent the acquisition data in the form of a plurality of points having a set of coordinates in a three-dimensional reference frame, - a biomechanical measurement device comprising a probe holder (200) designed to rigidly connect at least one ultrasonic probe (210) for imaging the vascular system relating to said limb (110) and a force sensor (220) designed to measure the pressure exerted by said probe (210) on the limb (110), and - an analysis device, designed to both merge at least a part of the volumetric data and at least a part of the anatomical and biomechanical data, and to determine the morphological variables of the limb (110) and/or the biomechanical variables of the vascular system of said limb.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof

Abstract

The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD 146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD 146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention concerns an endoprosthesis (1) comprising: a main tubular endoprosthesis (10) having an inside surface (20), at least one lateral jamb (100), said lateral jamb (100) comprising a tubular jamb body (110) and a jamb stent (120), with the jamb stent (120) being at least partially covered by the tubular jamb body (110), the proximal end (111) of the lateral jamb (100) comprising a flange (30) substantially extending in the direction of the distal end (112) of the lateral jamb (100), characterised in that the lateral jamb (100) is inserted into an orifice (130) of the main tubular endoprosthesis (10) such that the flange (30) rests on the inside surface (20) of the main tubular endoprosthesis (10). The present invention furthermore concerns a jamb, a method of assembly of an endoprosthesis, an insertion system and an assembly kit of an endoprosthesis.

IPC Classes  ?

• A61F 2/07 - Stent-grafts

Abstract

The present invention relates to a hydrophobic polymer used in particular to produce and/or coat medical devices, in particular implantable medical devices, that are visible in magnetic resonance imaging, characterized in that it comprises at least one monomer unit on which is grafted a chelating ligand of a paramagnetic ion complexed with such a paramagnetic ion, said monomer unit having at least one carbonyl group, said monomer unit comprising, prior to grafting, at least one hydrogen atom in the α position of said at least one carbonyl group, and said grafting of the chelating ligand taking place in the area of said at least one hydrogen atom in the α position of said at least one carbonyl group.

IPC Classes  ?

• A61L 27/14 - Macromolecular materials
• A61L 27/34 - Macromolecular materials
• A61L 29/14 - Materials characterised by their function or physical properties
• A61L 31/14 - Materials characterised by their function or physical properties
• C08F 30/04 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal